Evidence map›Paper›PMID 25042999›Full record

ArticleNature2014

Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.

James B Whitney, Alison L Hill, Srisowmya Sanisetty, Pablo Penaloza-MacMaster, Jinyan Liu, Mayuri Shetty, Lily Parenteau, Crystal Cabral, Jennifer Shields, Stephen Blackmore and 16 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 445 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
445citing papers in PubMed, 4 pooled it
31.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

445 citing papers in PubMed, 4 syntheses or guidelines pooled it, 626 citations in OpenAlex.

  1. Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  2. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  3. Guideline
  4. The Hitchhiker Guide to CD4Frontiers in immunology · 2021
    Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular therapy. Nucleic acids · 2026
    Article
  11. The immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. HCV-specific CD4EBioMedicine · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Maintenance of intestinal CX3CR1Nature communications · 2026
    Article
  20. Article

385 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 1 country.

James B Whitney1] Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA [2] Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts 02139, USA.
Alison L HillProgram for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts 02138 USA.
Srisowmya SanisettyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Pablo Penaloza-MacMasterCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Jinyan LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Mayuri ShettyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Lily ParenteauCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Crystal CabralCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Jennifer ShieldsCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Stephen BlackmoreCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Jeffrey Y SmithCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Amanda L BrinkmanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Lauren E PeterCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Sheeba I MathewCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Kaitlin M SmithCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Erica N BorducchiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Daniel I S RosenbloomProgram for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts 02138 USA.
Mark G LewisBioqual, Rockville, Maryland 20852, USA.
Jillian HattersleyGilead Sciences, Foster City, California 94404, USA.
Bei LiGilead Sciences, Foster City, California 94404, USA.
Joseph HesselgesserGilead Sciences, Foster City, California 94404, USA.
Romas GeleziunasGilead Sciences, Foster City, California 94404, USA.
Merlin L RobbUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA.
Jerome H KimUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA.
Nelson L MichaelUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA.
Dan H Barouch1] Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA [2] Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts 02139, USA.
Beth Israel Deaconess Medical Center · USGilead Sciences (United States) · USWalter Reed Army Institute of Research · USHarvard University · USBioqual · USRagon Institute of MGH, MIT and Harvard · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 VaccineU19AI078526 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2008 to 2012
$44.0M
VirologyU19AI095985 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BURTON, DENNIS R. · 2011 to 2015
$35.9M
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 VaccinesU19AI096040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2012 to 2016
$18.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Impact of HIV Envelope Conformation on ImmunogenicityR01AI084794 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., CHEN, BING · 2009 to 2013
$4.0M
Mechanisms of SIV persistenceR56AI091514 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WHITNEY, JAMES BURTON · 2011 to 2011
$849k
NIAID NIH HHS AI060354NIAID NIH HHS AI078526NIAID NIH HHS AI084794NIAID NIH HHS AI095985NIAID NIH HHS AI096040NIAID NIH HHS AI100645NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI084794NIAID NIH HHS R56 AI091514NIAID NIH HHS T32 AI007245NIAID NIH HHS U19 AI078526NIAID NIH HHS U19 AI095985NIAID NIH HHS U19 AI096040NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1) eradication strategies. However, it remains unclear when and where the viral reservoir is seeded during acute infection and the extent to which it is susceptible to early antiretroviral therapy (ART). Here we show that the viral reservoir is seeded rapidly after mucosal simian immunodeficiency virus (SIV) infection of rhesus monkeys and before systemic viraemia. We initiated suppressive ART in groups of monkeys on days 3, 7, 10 and 14 after intrarectal SIVMAC251 infection. Treatment with ART on day 3 blocked the emergence of viral RNA and proviral DNA in peripheral blood and also substantially reduced levels of proviral DNA in lymph nodes and gastrointestinal mucosa as compared with treatment at later time points. In addition, treatment on day 3 abrogated the induction of SIV-specific humoral and cellular immune responses. Nevertheless, after discontinuation of ART following 24 weeks of fully suppressive therapy, virus rebounded in all animals, although the monkeys that were treated on day 3 exhibited a delayed viral rebound as compared with those treated on days 7, 10 and 14. The time to viral rebound correlated with total viraemia during acute infection and with proviral DNA at the time of ART discontinuation. These data demonstrate that the viral reservoir is seeded rapidly after intrarectal SIV infection of rhesus monkeys, during the 'eclipse' phase, and before detectable viraemia. This strikingly early seeding of the refractory viral reservoir raises important new challenges for HIV-1 eradication strategies.

Indexed as

Viral LoadAnimalsAnti-Retroviral AgentsCarrier StateDisease Models, AnimalDNA, ViralFemaleKineticsMacaca mulattaMaleProvirusesRectumRNA, ViralSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTime FactorsAnti-Retroviral AgentsDNA, ViralRNA, Viral

Identifiers

PMID25042999
PMCPMC4126858
OpenAlexW2156075763

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.